Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates

KIMBERLEY S ADAMS,1 DAVID H ABRAMSON,2 ROBERT M ELLSWORTH,2 BARRETT G HAIK,2 MICHAEL BEDFORD,3 SAMUEL PACKER1 JOHANNA SEDDON,1 DANIEL ALBERT,5 AND LEILA POLIVOGIANI5

From the Departments of Ophthalmology, 1Manhattan Eye, Ear and Throat Hospital; the 2New York Hospital-Cornell Medical Center, New York, New York; 3St Bartholomew’s Hospital, London, England; 4North Shore Hospital, Manhasset, New York; and 5Harvard Medical School, Boston, Massachusetts, USA

SUMMARY Two hundred and twenty-three patients treated by cobalt plaque for uveal melanoma were compared with 416 patients treated by enucleation for uveal melanoma in terms of patient survival. The median follow-up time for the patients treated by cobalt plaque was 4-3 years. Kaplan-Meier survival curves were calculated up to five years following treatment based on time to tumour-related deaths. Cox’s proportional hazards multivariate analysis was performed to determine which variables were related to melanoma-related deaths while controlling for age, size, and location of the tumours. Statistically significant predictive factors were location of tumour and largest tumour dimension. There was not a statistically significant difference in survival between patients treated by cobalt plaque and those treated by enucleation.

Many studies have explored prognostic factors and survival rates for patients with malignant melanoma of the choroid and ciliary body treated by enucleation.1-4 A few studies have investigated similar factors with respect to treatment with cobalt-60 plaque therapy, but these have involved small numbers of patients and short follow-up times.5-8 There has been, and continues to be, much discussion concerning the pros and cons of various types of treatment for malignant melanoma. The most basic issue in these debates would appear to be patient survival, yet no long-term study on a large patient population comparing treatment by enucleation with cobalt plaque, in terms of survival, exists. Comparison of prior studies is difficult: tumour dimensions have been variable, different methods of analysis have been used, patient numbers are small, and follow-up time short.3 This study compares survival in terms of melanoma-related deaths between cobalt-60 plaque-treated patients (with long-term follow-up from multiple institutions in the United States and one in England) and patients treated by enucleation from the Massachusetts Eye and Ear Infirmary.

Material and methods

Three groups of patients with choroidal and ciliary body melanoma were compared for survival. Two hundred and sixty-seven patients, with a diagnosis of uveal melanoma from 1953 to 1973, treated by enucleation were identified from the records of the Eye Pathology Laboratory at the Massachusetts Eye and Ear Infirmary (MEEI). Thirty-two patients with histological extrascleral extension were excluded, leaving a total of 235 cases for group I. These subjects have been described elsewhere9 and were part of a group of 267 cases with known survival status out of a total of 431 eligible patients.

Group II included 161 patients from MEEI with a diagnosis of choroidal and ciliary body melanoma whose eyes were enucleated from 1975 to 1981. From a total of 231 patients treated by enucleation during this period 20 were excluded because of extrascleral extension, and the survival status was unknown for another 50 patients.

Group III consisted of 223 patients with a diagnosis of uveal melanoma on the basis of clinical examination, indirect ophthalmoscopy, ultrasonography, and fluorescein angiography, treated by cobalt-60 plaque at several institutions: 142 cases from 1968 to 1981 identified from the records at the New York Hospital.
and Manhattan Eye, Ear and Throat Hospital; seven cases treated from 1975 to 1977 identified at North Shore University Hospital, New York; and 74 cases treated from 1954 to 1981 identified at St Bartholomew’s Hospital, London. No patients had known extrascleral extension at the time of cobalt plaquing and all patients were included in the study.

Survival status, the date and cause of death, and metastatic disease status were determined up to 1 May 1983 in the enucleation groups and up to June 1984 in the cobalt plaque group by chart review, contact with patients, and their families, as well as contact with physicians. Survival status was recorded as alive without known metastases, alive with metastases, dead secondary to metastatic uveal melanoma, or dead from other causes. Metastases were confirmed by liver function abnormalities biopsy, or necropsy.

Tumour dimensions for the enucleation group were obtained from review of histopathological studies: the largest tumour diameter in millimetres in contact with the sclera, and elevation of the tumour in millimetres measured on the largest section available. For the cobalt plaque group the tumour dimensions were determined by visualisation by indirect ophthalmoscopy or by ultrasonographic measurements. The largest tumour dimension for each tumour, either diameter or height, was used in the analysis.

The location of the anterior margin of the tumour was coded as posterior to the equator or anterior to the equator, with or without involvement of the ciliary body.

Survival curves, based on deaths from uveal melanoma for the first five years after treatment for all three treatment groups, were calculated by the Kaplan-Meier technique. Cox’s proportional hazards multivariate analysis was performed to determine which variables were independently associated with melanoma-related deaths. The four variables considered in the Cox model were: (1) treatment: cobalt-60 plaque, enucleation 1953–73, and enucleation 1975–81; (2) age: less than 40 years, 40–59 years, 60 years and older; (3) location of tumour: posterior to the equator or anterior to the equator; (4) largest tumour dimension (either diameter or height): small (up to 11 mm), medium (11–15 mm), or large (16 mm or greater).

The statistical analyses were performed through the computer facilities of the Department of Ophthalmology at the Massachusetts Eye and Ear Infirmary.

**Results**

The median age at enucleation of patients with uveal melanoma in group I (1953–73) was 58.5 years with a range of 18 to 95 years; in group II (1975–81), the median was 60 years with a range of 10 to 94 years. The age at cobalt plaque treatment for choroidal and ciliary body melanoma patients in group III ranged from 22 years to 84 years, with a median of 57.0 years. For two of the 223 cobalt plaque patients age at the time of treatment was not available.

Table 1 shows the distribution of characteristics according to treatment group.

The follow-up time in enucleation group I ranged from 100 days to 28 years, with a median of 9.3 years. In group II the follow-up time ranged from 90 days to 8.5 years, with a median of 3.3 years. In group III, the cobalt plaque group, the follow-up time ranged from 30 days to 30 years, with a median of 4.3 years.

Thirty-six of the 223 patients treated by cobalt plaque for uveal melanoma underwent subsequent enucleation. Of these 36 patients 4 died of metastatic melanoma and one of other causes. Among the 188 patients treated only by cobalt plaque there were 18 deaths from metastatic disease and 11 from other causes. The analyses of patient survival comparing cobalt plaque treatment with enucleation were performed for all 223 cobalt plaque patients, including those 36 who underwent eventual enucleation. A further analysis was also made comparing the two enucleation groups, I and II, with the cobalt plaque group, excluding those with subsequent enucleation.

**Survival curves**

Kaplan-Meier survival curves were calculated from tumour deaths for the first five years after treatment for all three treatment groups (Fig. 1); for only small
patients treated by enucleation from 1953 to 1973 (Fig. 3). Other comparisons were not significantly different.

Variables related to survival
Cox’s proportional hazards multivariate analysis, including the variables previously mentioned (treatment, age, location of tumour, largest tumour dimension), showed that anterior location and largest tumour dimensions (11–15 mm and 16 mm and greater) were significant prognostic factors for uveal melanoma related deaths (Table 2). Patients with anterior tumours were twice as likely to die from melanoma in the first five years of follow-up as were patients with posterior tumours. In addition patients with tumours with 11–15 mm as the largest tumour dimension were 1.86 times as likely to die of tumour as patients with tumours 1–10 mm, and patients with tumours 16 mm or greater had a rate of melanoma death 3.3 times that of patients with a tumour 1–10 mm. When these and other factors previously mentioned were controlled, there was no significant difference in survival between the cobalt plaque treated patients and enucleation. Thirty-six of the 223 cobalt plaque treated patients eventually underwent enucleation. When these patients were excluded from the analyses, Kaplan-Meier curves showed no difference in survival between cobalt plaque patients and either enucleation group. This group was also analysed by means of the Cox model, which showed results similar to the analysis presented above, including all cobalt plaque patients.

Discussion
Previous studies of patient survival in choroidal and ciliary body melanoma have largely been directed

Table 2 Results of Cox model analysis for deaths related to uveal melanoma

<table>
<thead>
<tr>
<th>Variable</th>
<th>Comparison</th>
<th>Estimated rate ratio*</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>Enucleation group 1 vs cobalt</td>
<td>1.07</td>
<td>0.59–1.95</td>
</tr>
<tr>
<td></td>
<td>Enucleation group 2 vs cobalt</td>
<td>0.77</td>
<td>0.39–1.51</td>
</tr>
<tr>
<td>Age</td>
<td>40–59 vs &lt;40</td>
<td>0.84</td>
<td>0.34–2.05</td>
</tr>
<tr>
<td></td>
<td>60+ vs &lt;40</td>
<td>1.64</td>
<td>0.70–3.87</td>
</tr>
<tr>
<td>Location</td>
<td>Anterior vs posterior</td>
<td>2.07</td>
<td>1.27–3.37</td>
</tr>
<tr>
<td>Largest tumour dimension</td>
<td>11–15 vs &lt;11</td>
<td>1.80</td>
<td>1.06–3.04</td>
</tr>
<tr>
<td></td>
<td>16+ vs &lt;11</td>
<td>3.31</td>
<td>1.67–6.55</td>
</tr>
</tbody>
</table>

*Estimated by the antilogarithm of the regression coefficients from proportional hazards model, with adjustment for all other variables presented.
Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates

toward one type of treatment. In terms of enucleation Flocks et al. in 1955 had 73 out of 210 melanoma related deaths, McLean et al. in 1977 had 76 out of 217, Shammas and Blodi in 1977 had 87 out of 293, and Seddon and Albert in 1983 had 110 out of 274, with an average overall mortality of 34%.

Studies of patient survival with cobalt plaque treatment include those of Stallard in 1966 with six melanoma related deaths out of 100, MacFaul in 1977 with 12 out of 107, Ellsworth in 1978 with five out of 47, Migdal in 1983 with five out of 90, and Brady and Shields in 1984 with three out of 100, with an average overall mortality of 7%. Variable follow-up time makes meaningful comparison of these studies difficult.

A prior study comparing mortality data on a group of 100 patients treated by cobalt plaque with 100 patients treated by enucleation matched for age, sex, size of tumour, and follow-up from the Hahennmann-Wills Eye Hospital Group indicated for the cobalt plaque group a death rate of 0% for small, 2-4% for medium-sized, and 3-8% for large-sized melanomas. For their enucleation group death rates of 8-3%, 4-5%, and 22% respectively were found.

In contrast Gass found a 50% probability of melanoma related death within five years after cobalt plaque in 21 patients, compared with 16% after enucleation in 27 patients.

Our study compares patient survival for cobalt plaque versus enucleation in a larger group of patients for a longer follow-up time for equally sized, aged, and located tumours by the same methods of analysis as have previously been described. Ocular survival, visual acuity, and radiation complications from cobalt plaquing, all important considerations in terms of type of treatment, were not included in this study but will be examined at a later date.

In conclusion, as in prior studies, overall patient survival for cobalt plaque is better than enucleation. As in prior studies of enucleation, survival for cobalt plaque is poorest with anterior tumours and is best with smallest tumours.

For equal sized tumours, at the same location with equal follow-up, survival with cobalt plaque is at least equal to survival with enucleation. Therefore, if enucleation for a uveal melanoma is planned, cobalt plaque should be considered: the cure rate is the same, and obviously ocular survival, vision, and cosmesis are better.

References

Accepted for publication 18 May 1987.